Rocket Pharmaceuticals (RCKT) Other Accumulated Expenses (2014 - 2026)

Rocket Pharmaceuticals has reported Other Accumulated Expenses for 13 years, with the latest figure at $4.2 million in Q1 2026.

• Quarterly Other Accumulated Expenses rose 43.4% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 million (up 43.4% YoY) and the FY2025 annual result came in at $2.3 million, up 43.45% from the prior year.
• Other Accumulated Expenses climbed to $4.2 million in Q1 2026 per RCKT's latest filing, from $2.3 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $4.2 million in Q1 2026 and troughed at $645000.0 in Q2 2022.
• A 5-year average of $2.1 million and a median of $1.9 million in 2022 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2025: Other Accumulated Expenses jumped 371.58% in 2022, then sank 44.17% in 2025.
• Over 5 years, Other Accumulated Expenses stood at $2.3 million in 2022, then slipped by 22.04% to $1.8 million in 2023, then dropped by 8.3% to $1.6 million in 2024, then surged by 43.45% to $2.3 million in 2025, then surged by 81.17% to $4.2 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $4.2 million, $2.3 million, and $2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.